You are here
PHRIXUS PHARMACEUTICALS, INC.
UEI: N/A
# of Employees: 2
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Treatment of Muscular Dystrophy-associated Dilated Cardiomyopathy with P-188
Amount: $622,877.00DESCRIPTION (provided by applicant): The long-term goal of this project is to obtain FDA approval to market Poloxamer-188 (P- 188) for the prevention and treatment of dilated cardiomyopathy (DCM) and ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Effects of P-188 on Respiratory Function and Diaphragm Degeneration in the mdx mo
Amount: $583,225.00DESCRIPTION (provided by applicant): The long-term goal of this project is to develop Poloxamer-188 (P-188) for the delay or prevention of respiratory deficits in patients with Duchenne muscular dystr ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
CREATION OF STANDARDS AND DEVELOPMENT OF MOLECULAR CLINICAL DIAGNOSTIC FOR ENTERI
Amount: $153,916.00DESCRIPTION (provided by applicant): This one-year phase I SBIR proposal will apply the benefits of molecular testing, in terms of speed, sensitivity, and ultimately value, to diagnose enteric Microsp ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
SBIR Phase I: Standardizing Microbial Water Quality Monitoring Using Synthetic Biology
Amount: $101,684.00This SBIR Phase I project will develop positive controls based on existing genetic sequencing data to generate sufficient quantities of positive control DNA from whole organisms for PCR-based pathogen ...
SBIRPhase I2010National Science Foundation -
Poloxamer 188 mechanism of action in ischemic heart failure.
Amount: $306,708.00DESCRIPTION (provided by applicant): This project was initiated to determine how Poloxamer-188 (P-188) improves cardiac function in ischemic heart failure (HF). While it is accepted that lack of oxyge ...
STTRPhase I2010Department of Health and Human Services National Institutes of Health -
Development of Poloxamer-188 for the Treatment of Muscular Dystrophy Associated H
Amount: $379,487.00DESCRIPTION (provided by applicant): This application focuses on initial preclinical steps required to develop Poloxamer-188 (P-188) for the treatment of heart failure (HF) associated with Duchene and ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Real-time PCR Diagnostic Kit for Giardia and Cryptosporidium
Amount: $958,924.00DESCRIPTION (provided by applicant): This two-year proposal seeks small business support for IDX Labs LLC to continue collaborating with Dr. Houpt at the University of Virginia to bring sensitive real ...
STTRPhase II2008Department of Health and Human Services National Institutes of Health -
Poloxamer-188 for the prevention of fibrosis during peritoneal dialysis
Amount: $277,646.00DESCRIPTION (provided by applicant): Project Summary. This application is focused on preventing adverse events associated with chronic peritoneal dialysis (PD), a renal replacement the ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Targeted DNA extraction for Tuberculosis PCR from sputum
Amount: $275,497.00DESCRIPTION (provided by applicant): Present diagnostic methods for active Tuberculosis are inadequate. Acid fast staining and microscopy of sputum is insensitive, particularly in advanced AIDS when a ...
STTRPhase I2007Department of Health and Human Services National Institutes of Health -
Chronic Treatment of Heart Failure With Poloxamer-188
Amount: $215,084.00DESCRIPTION (provided by applicant): Heart failure (HF) is a major medical problem in the United States affecting more than 5 million patients. It is expected to impact 11 million patients by 2011. Of ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health
